Vir Biotechnology Inc
VIR5.180USD
+0.380+7.92%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
719.43MMarket Cap
LossP/E TTM
More Details of Vir Biotechnology Inc Company
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Company Info
Ticker SymbolVIR
Company nameVir Biotechnology Inc
IPO dateOct 11, 2019
CEODr. Marianne De Backer, Ph.D.
Number of employees408
Security typeOrdinary Share
Fiscal year-endOct 11
Address1800 Owens Street
CitySAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94158
Phone14159064324
Websitehttps://www.vir.bio/
Ticker SymbolVIR
IPO dateOct 11, 2019
CEODr. Marianne De Backer, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-30.05%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
23.81K
+50.61%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
19.03K
-80.53%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
+120.86%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
8.00K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
4.69K
-94.10%
Dr. Mark Eisner, M.D.
Dr. Mark Eisner, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Ms. Janet Napolitano, J.D.
Ms. Janet Napolitano, J.D.
Independent Director
Independent Director
--
--
Mr. Jason V. O'byrne
Mr. Jason V. O'byrne
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Vicki L. Sato, Ph.D.
Dr. Vicki L. Sato, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-30.05%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
23.81K
+50.61%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
19.03K
-80.53%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
+120.86%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
8.00K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
4.69K
-94.10%
Revenue Breakdown
FY2024
No Data
By RegionUSD
Name
Revenue
Proportion
United States
74.20M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
SB Investment Advisers (UK) Limited
12.01%
BlackRock Institutional Trust Company, N.A.
9.97%
The Vanguard Group, Inc.
9.50%
ARCH Venture Partners
9.30%
GSK plc
6.16%
Other
53.06%
Shareholders
Shareholders
Proportion
SB Investment Advisers (UK) Limited
12.01%
BlackRock Institutional Trust Company, N.A.
9.97%
The Vanguard Group, Inc.
9.50%
ARCH Venture Partners
9.30%
GSK plc
6.16%
Other
53.06%
Shareholder Types
Shareholders
Proportion
Investment Advisor
30.20%
Investment Advisor/Hedge Fund
15.37%
Private Equity
13.73%
Venture Capital
9.94%
Hedge Fund
7.64%
Corporation
6.16%
Individual Investor
4.33%
Research Firm
2.30%
Foundation
1.12%
Other
9.22%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
530
124.85M
89.88%
-15.28M
2025Q1
571
125.80M
91.30%
-16.44M
2024Q4
568
122.14M
89.06%
-13.83M
2024Q3
554
118.76M
86.83%
-17.44M
2024Q2
572
119.53M
87.47%
-20.55M
2024Q1
564
122.68M
91.07%
-16.10M
2023Q4
577
121.87M
90.75%
-16.40M
2023Q3
578
123.93M
92.29%
-3.81M
2023Q2
574
125.10M
93.31%
+332.42K
2023Q1
568
121.09M
90.65%
+1.82M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
SB Investment Advisers (UK) Limited
16.68M
12.07%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
14.37M
10.4%
-298.87K
-2.04%
Mar 31, 2025
The Vanguard Group, Inc.
12.78M
9.25%
-323.13K
-2.47%
Mar 31, 2025
ARCH Venture Partners
12.92M
9.34%
--
--
Apr 01, 2025
GSK plc
8.55M
6.19%
--
--
Apr 01, 2025
State Street Global Advisors (US)
5.73M
4.14%
+652.43K
+12.86%
Mar 31, 2025
Scangos (George A)
3.78M
2.73%
-550.77K
-12.72%
Apr 01, 2025
Citadel Advisors LLC
1.62M
1.17%
+1.35M
+496.18%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.68M
1.94%
+768.95K
+40.14%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
